Economic studies of immunotherapy: A review

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 6, 2008, Pages 585-589

  Berto, Patrizia ^a,b   Frati, Franco ^c,d   Incorvaia, Cristoforo ^e  

^a UNIVERSITY OF PADOVA   (Italy)

^b Pbe Consulting   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d Medical and Scientific Department   (Italy)

^e ICP Hospital   (Italy)

Author keywords

Allergens; Asthma; Costs; Economics; Immunology; Immunotherapy; Rhinitis

Indexed keywords

ALLERGOVIT; ALUSTAL; ALUTARD; CORTICOSTEROID DERIVATIVE; GRASS POLLEN VACCINE; IMMUNOMODULATING AGENT; PARIETARIA EXTRACT; PHLEUM PRATENSE EXTRACT; PHOSTAL; PURETHAL; STALORAL; TYROSIN ALLERGOID; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; CHILD CARE; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG MEGADOSE; ECONOMIC EVALUATION; HAY FEVER; HEALTH CARE SYSTEM; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; MEDICAL DECISION MAKING; PARIETARIA; PERENNIAL RHINITIS; PHLEUM PRATENSE; POLLEN ALLERGY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SOCIAL ASPECT; TREATMENT OUTCOME;

ASTHMA; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION ROUTES; ECONOMICS; GUIDELINES AS TOPIC; HEALTH CARE COSTS; HUMANS; IMMUNOTHERAPY; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 56749183325     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32831411e9     Document Type: Review

References (28)

1. Bousquet J, Van CP, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (5 Suppl):S147-S334.
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl 86):8-160.
3. Schunemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006; 174:605-614.
4. ISPOR. Healthcare, cost, quality and outcomes - ISPOR book of terms. 2003.
5. Drummond M, O'Brien B, Stoddard G, Torrance G. Methods for the economic evaluation of healthcare programmes. Second ed. New York: Oxf.Un.Press; 1997.
6. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxf.Un.Press; 1996.
7. Berto P. Pharmacoeconomics and Immunotherapy. Eur Ann Allergy Clin Immunol 2007; 39 (Special Number):12-16. This paper is useful for a detailed description of the different methods for economic evaluation with a special focus on rhinitis, asthma and immunotherapy.
8. Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999; 103 (3 Pt 1):401-407.
9. Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004; 11:17-33.
10. Smith AF, Pitt AD, Rodruiguez AE, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 2005; 12:233-242.
11. Donahue JG, Greineder DK, Connor-Lacke L, et al. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol 1999;82:339-347.
12. Berto P, Bassi M, Incorvaia C, et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Allerg Immunol (Paris) 2005; 37:303-308.
13. Ariano R, Berto P, Tracci D, et al. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006; 27:159-163.
14. Berto P, Frati F, Incorvaia C, et al. Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. Curr Med Res Opin 2008; 24:261-266. This paper has shown the relevant economic benefit of immunotherapy, as measured in an observational practice environment, right at the first year of treatment.
15. Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol 2008; 121:227-232. The most recent cost-to-cost comparison of subcutaneous immunotherapy.
16. Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17:37-52.
17. Berto P, Passalacqua G, Crimi N, et al. Economic evaluation of sublingual immunotherapy versus symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol 2006; 97:615-621.
18. Bachert C, Vestenbaek U, Christensen J, et al. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Clin Exp Allergy 2007; 37:772-779.
19. Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir Med 2007; 101:1885-1894.
20. Keiding H, Jorgensen KP. A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. Curr Med Res Opin 2007; 23:1113-1120.
21. Omnes LF, Bousquet J, Scheinmann P, et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Allerg Immunol (Paris) 2007; 39:148-156.
22. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99 (1 Ft 1):22-27.
23. Smith DH, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156 (3 Pt 1):787-793.
24. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 1994; 73:35-39.
25. Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Ann Allergy, Asthma Immunol 2008; 100:482-489. Another very recent and interesting approach to economic comparison of sublingual versus subcutaneous immunotherapy.
26. Wikipedia. Break-even. http://en.wikipedia.org/wiki/Break-even 2008 May 20.
27. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434-440.
28. Poulsen PB, Pedersen KM, Christensen J, Vestenbaek U. Economic evaluation of a tablet-based vaccination against hay fever in Denmark. Ugeskr Laeger 2008; 170:138-142.